Skip Navigation
Skip to contents

CPP : Cardiovascular Prevention and Pharmacotherapy

Sumissioin : submit your manuscript
SEARCH
Search

Author index

Page Path
HOME > Browse articles > Author index
Search
Kyung-Jin Kim 1 Article
Vasopressin Receptor Antagonist, Tolvaptan, for Treating Hyponatremia in Patients with Heart Failure
Kyung-Jin Kim
Cardiovasc Prev Pharmacother. 2021;3(1):10-14.   Published online January 31, 2021
DOI: https://doi.org/10.36011/cpp.2021.3.e3
  • 2,954 View
  • 76 Download
  • 1 Citations
Abstract PDF
Hyponatremia is common in hospital setting in patients with heart failure and is associated with increased morbidity and mortality. However, despite these complications, appropriate treatment strategies other than established therapies such as hypertonic saline, loop diuretics, and fluid restriction are limited. Tolvaptan, a vasopressin receptor antagonist, has aquaretic effects that excrete free water and dilutes urine, thereby increasing serum sodium concentration. This new approach might be a landmark in the treatment of hyponatremia as there is a lack of controlled studies in this field. However, regardless of the associated advantage, tolvaptan is recommended to be used for less than 30 days owing to the possibility of liver injury. This study is aimed to present the clinical use of tolvaptan for hyponatremia in patients with heart failure.

Citations

Citations to this article as recorded by  
  • The role of tolvaptan add-on therapy in patients with acute heart failure: a systematic review and network meta-analysis
    Vireza Pratama, Jordan Budiono, Jarir At Thobari, Bambang Widyantoro, Vita Yanti Anggraeni, Lucia Kris Dinarti
    Frontiers in Cardiovascular Medicine.2024;[Epub]     CrossRef

CPP : Cardiovascular Prevention and Pharmacotherapy